Error: Twitter did not respond. Please wait a few minutes and refresh this page.
Author Archives: Barbara Arzymanow
The first point that I must make is that I do not wish to appear unappreciative or condescending. Hospital A&E work is amongst the most important that any person can undertake and many of us would find the strain unbearable. … Continue reading
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
The economic consequences of preventing illness are highly complex. Just comparing the costs of prevention with the direct treatment costs that should be avoided is far too simplistic. The true economic impact of preventative measures can often only be assessed … Continue reading